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Background: Fucoxanthin is a xanthophyll present in brown seaweeds and has several beneficial effects, including
anti-obesity and anti-diabetic effects. However, we and another group previously observed that fucoxanthin
increases serum cholesterol levels in rodents. Cholesterol is an important component of cell membranes and
biosynthesis of bile acids. Serum cholesterol levels are also closely associated with atherosclerosis. Therefore,
we sought to identify the mechanism underlying the increase in serum cholesterol levels by fucoxanthin.
Methods: Diabetic/obese KK-Ay mice were fed a diet containing 0.2% fucoxanthin for 4 weeks. The mice were
sacrificed, and total blood samples were collected for the measurement of serum total cholesterol, HDL-cholesterol
and non-HDL-cholesterol levels. Cholesterol content in tissues was also analyzed. Real-time PCR and Western
blotting were performed to determine hepatic mRNA and protein expression of genes involved in cholesterol
metabolism, respectively.
Results: Dietary fucoxanthin significantly increased serum HDL and non-HDL cholesterol levels, and reduced
hepatic cholesterol content. In liver, the expression of SREBP1, SREBP2 and their target genes involved in cholesterol
biosynthesis significantly increased and tended to increase in the fucoxanthin-fed mice, respectively. In contrast,
hepatic levels of LDLR and SR-B1 proteins which is important factors for LDL-cholesterol and HDL-cholesterol
uptake in the liver from serum, decreased to 60% and 80% in the fucoxanthin-fed mice, respectively, compared
with the control mice. Further, we found that dietary fucoxanthin significantly increased the mRNA expression
of proprotein convertase subtilisin/kexin type 9 (PCSK9), which enhances intracellular degradation of LDLR
in lysosomes.
Conclusions: Fucoxanthin increased HDL-cholesterol and non-HDL-cholesterol levels in KK-Ay mice by inducing
SREBP expression and reduced cholesterol uptake in the liver via down-regulation of LDLR and SR-B1, resulted in
increased serum cholesterol in the mice.
Keywords: Fucoxanthin, Cholesterol metabolism, Liver, Sterol regulatory element binding protein (SREBP),
Low-density lipoprotein (LDL) receptor (LDLR), Scavenger receptor class B type 1 (SR-B1), Proprotein convertase
subtilisin/kexin type 9 (PCSK9)Introduction
Fucoxanthin is an orange-colored carotenoid present in
edible brown seaweeds, such as Undaria pinnatifida and
Hijikia fusiformis. Fucoxanthin has reported to exhibit
beneficial health effects, such as anti-cancer [1], anti-
inflammatory [2], and radical scavenging [3] activities.
We previously reported that fucoxanthin suppresses body* Correspondence: hoso@fish.hokudai.ac.jp
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reproduction in any medium, provided the orweight gain and ameliorates hyperglycemia in diabetic/
obese KK-Ay mice [4].
On the other hand, Kadekaru et al. reported that oral
fucoxanthin administration for 28 days significantly
increased serum total-cholesterol levels in male and
female rats [5]. We also observed an increase in serum
total cholesterol levels in ICR mice administered a high
dose of fucoxanthin (500 mg/kg body weight) for 30 days
[6]. In contrast, Woo et al. reported that fucoxanthin
(0.2% in diet) decreased plasma cholesterol levels in
C57BL/6N mice fed a high-fat diet [7]. Thus, the effectsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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In addition, the effects of fucoxanthin on regulation of
cholesterol transport and metabolism have not been
investigated in detail.
Cholesterol is an essential component of plasma mem-
branes and lipoproteins and is a precursor of internal
steroids, such as corticosteroids, sex hormones, bile
acids, and vitamin D. Cholesterol levels in the blood and
tissues are regulated by a balance between biosynthesis
and catabolism, which primarily involve the activities of
3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reduc-
tase and cholesterol 7 α-hydroxyrase (CYP7A1), respect-
ively. The expression of genes involved in cholesterol
synthesis is strictly regulated by sterol regulatory elem-
ent binding protein (SREBP) 1 and SREBP2. In addition,
low-density lipoprotein (LDL) receptor (LDLR), scaven-
ger receptor class B type 1 (SR-B1), and ATP-binding
cassette transporter A1 (ABCA1) play crucial roles in
the uptake and efflux of cholesterol in the liver and
peripheral tissues to control the cholesterol levels in
the body.
In the present study, we investigated the effects of
fucoxanthin on the molecular mechanism underlying
cholesterol metabolism in diabetic/obese KK-Ay mice.
Dietary fucoxanthin (0.2% in the diet) increased HDL-
cholesterol and non-HDL-cholesterol levels as well as
total cholesterol levels in the serum of KK-Ay mice. Hep-
atic SREBP2 expression was also increased by fucoxan-
thin, although hepatic cholesterol content decreased.
Fucoxanthin resulted in reduced LDLR expression
through up-regulation of hepatic expression of PCSK9
mRNA. In addition, the SR-B1 expression level in the
liver was also decreased by fucoxanthin. Our results
reveal that fucoxanthin affects on cholesterol metabol-
ism and transport system, which alters the cholesterol
balance among the serum, liver, and peripheral tissues.Table 1 Composition of experiment diets based on
AIN-93G
Ingredient Control (g/kg) Fucoxanthin
Corn starch 397.486 397.486
Casein 200 200
Sucrose 100 100
Dextrinized corn starch 132 132
Soybean oil 70 68Materials and methods
Materials
Dried brown seaweed, Undaria pinnatifida, was pur-
chased from a market in Hakodate, Hokkaido in Japan.
Anti-SREBP2, anti-LDLR and anti-ABCA1 antibodies
were obtained from Abcam (Cambridge, MA, USA).
Anti-SREBP1 and anti-SR-B1 were purchased from Santa
Cruz Biotechnology (Santa Cruz, California, USA).Cellulose 50 50
Mineral mix 35 35
Vitamin mix 10 10
L-Cystine 3 3
Coline bitartrate 2.5 2.5
tert-Burtylhydroquinone 0.014 0.014
Fucoxanthin – 2.0Fucoxanthin preparation
Crude lipid containing fucoxanthin was extracted from
dried Undaria pinnatifida powder with acetone. Fucoxan-
thin was purified by silicagel column chromatography with
n-hexane/acetone (7:3, v/v) from the crude lipid as our
previous report [8]. Purity of fucoxanthin (all-trans- and
cis- fucoxanthin) was >95% by HPLC analysis.Animals and diet
Diabetic/obese KK-Ay mice (4-week old male) were pur-
chased from CLEA Japan, Inc. (Tokyo, Japan). The mice
had free access to drinking water and diet at 23 ± 1°C
and 50% humidity with a 12 h light/12 h dark cycle. The
diet was prepared according to the recommendations of
American Institute of Nutrition (AIN-93G). After accli-
mation for a week by feeding AIN-93G, KK-Ay mice
were assigned to two groups and fed the control diet
(AIN-93G) and fucoxanthin (0.2%) diet for 4 weeks
(Table 1). Blood samples were taken from caudal vena
cava of the mice fasted for 12 hour under ether
anesthesia. Then, liver, epididymal WAT, and skeletal
muscle were removed, weighed and immediately frozen
in liquid nitrogen for lipid analysis and Western blotting,
or soaked in RNA laterTM (Sigma Chemical Co., St.
Louis, MO) for quantitative real time PCR analysis. All
procedures for the use and care of animals for this re-
search were approved by the Ethical Committee of Ex-
perimental Animal Care at Hokkaido University.Serum and tissue cholesterol analysis
Serum total-cholesterol and HDL-cholesterol levels were
measured by each commercial assay kit (Wako pure che-
micals, Osaka, Japan) according to the manufacturer’s
instruction. Non-HDL-cholesterol was calculated by
subtraction of HDL-cholesterol from total-cholesterol.
Cholesterol content in tissue was measured by using a
technique as described by Jeon SM et al. [9]. In brief, tis-
sue lipids were extracted by Folch method [10]. An ap-
proximately 5 mg lipid was dissolved in 20 μl methanol/
Triton X-100 (1:1, v/v) and methanol was removed by
nitrogen gas. Distilled-deionized water was then added
and mixed until the solution was clear. Cholesterol con-
tent was measured using commercial enzymatic assay kit
Table 2 Total, HDL, and non-HDL cholesterol
concentrations in the serum
Control (mg/dl) Fucoxanthin
Total cholesterol 119.0 ± 10.3 169.2 ± 7.3**
HDL cholesterol 85.6 ± 5.2 109.1 ± 6.9*
Non-HDL cholesterol 33.4 ± 9.1 60.1 ± 4.9*
KK-Ay mice were fed with the AIN-93G diet with or without 0.2% fucoxanthin
for 4 weeks. Total and HDL-cholesterol was measured by an enzymatic
method. Non-HDL-cholesterol was calculated by subtracting HDL-cholesterol
from total-cholesterol. Each value represents the mean ± standard error (n = 6).
Asterisk show significant differences from the control group (*P < 0.05<,
**P < 0.01).
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according to the manufacturer’s instruction.
Quantitative real-time RT-PCR
Total RNA was isolated from the liver soaked in RNAla-
ter with the RNeasy Mini Kit (Qiagen, Tokyo, Japan),
according to the manufacturer’s protocol. Then, cDNA
was synthesized from total RNA using High Capacity
cDNA Reverse Transcription Kit (Applied Biosystems
Japan Ltd., Tokyo, Japan). Quantitative real-time PCR
analysis was carried out using the ABI Prism 7500 (Ap-
plied Biosystems Japan Ltd., Tokyo, Japan) with the Fas-
tStart Universal Probe Master (Rox) (Roche Diagnostics
Japan Ltd., Tokyo, Japan). The mRNA expression levels
were measured using the TaqmanW Gene Expression
Assays (Applied Biosystems Japan Ltd, Tokyo, Japan);
Hmgcr: Mm01282499_m1, Hmgcs: Mm01304569_m1,
Fdps: Mm00836315_g1, Lss: Mm00461312_m1, Cyp51:
Mm00490968_m1, Cyp7a1: Mm00484152_m1, PCSK9:
Mm01263610_m1 and β-Actin: Mm00607939_s1.
Western blotting
Liver was suspended in 10 volumes of a buffer con-
taining 50 mM Hepes, 150 mM NaCl, 1 mM EDTA,
2 mM EGTA, 50 mM sodium fluoride, 1% Triton X-
100 and 1 mM phenylmethylsulfonyl fluoride supple-
mented protease inhibitor cocktail (Sigma Chemical
Co., St. Louis, MO, USA). After centrifugation at
8,550 g for 60 min at 4°C, the supernatant was col-
lected for assay. Protein concentration in the super-
natant was determined by a colorimetric method
using a DC protein assay kit (Bio-Rad Laboratories,
Hercules, CA, USA). The lysates were mixed with the
same volume of loading buffer (Sigma Chemical Co.,
St. Louis, MO, USA), and boiled for 5 min. Protein
samples were loaded at 30 μg protein per lane, and
separated by SDS-polyacrylamide (10%) gel electro-
phoresis. Thereafter, proteins were transferred onto a
polyvinylidene difluoride membrane. The membrane
was blocked with 0.5% non-fat dry milk in TBS buffer
for 1 hour at room temperature. For detection of pro-
tein, the membranes were incubated with primary
anti-bodies for 1 hour at room temperature. After a
washing procedure, the membrane was incubated with
horseradish peroxidase-conjugated secondary antibody
(Santa Cruz Biotechnology, Inc., Santa Cruz, Califor-
nia, USA) for 1 hour at room temperature. The
immunoreactive bands were visualized with ECL Plus
Western Blotting Detection System (GE Healthcare
Japan Corporation, Japan). Quantitative densitometric
analyses were performed on digitized images of immu-
noblots using cooled CCD camera system (ATTO cor-
poration, Tokyo, Japan). The β-Actin was used for
loading standardization.Statistical analysis
Data are presented as the mean ± SEM. The statistical
significance between control and fucoxanthin groups
was analyzed by Student’s t-tests for each experiment.
Results
Cholesterol level in the serum, liver, white adipose tissue
and muscle
Fucoxanthin (0.2% in AIN-93G diet) suppressed body
weight gain of diabetic/obese KK-Ay mice as previous
papers [4]. Food intake of fucoxanthin-fed mice tended
to be lower, but not significantly, than that of control
mice. Dietary fucoxanthin significantly increased serum
total cholesterol levels in the KK-Ay mice (Table 2).
HDL-cholesterol and non-HDL-cholesterol levels also
increased in the fucoxanthin-fed mice. In contrast, hep-
atic cholesterol content was significantly lower in the
fucoxanthin-fed mice than in the control mice (Table 3),
although liver weight increased by fucoxanthin as our
previous study [6]. These effects of fucoxanthin were
associated with the amount of cholesterol per unit pro-
tein in the liver of the fucoxanthin-fed (26.36 ± 0.91) and
control mice (50.59 ± 5.46), respectively. The mechanism
by which fucoxanthin impacts on the liver is unclear.
The total amount of cholesterol that had accumulated
in epididymal WAT was also lower in the fucoxanthin-
fed mice than in the control mice because epididymal
WAT weight in the fucoxanthin-fed mice was lower than
that in the control mice (Table 3). On the other hand,
cholesterol level in skeletal muscle was not altered by
fucoxanthin. These results show that fucoxanthin
reduces the total cholesterol accumulation in the liver
and WAT.
Gene and protein expressions involved in cholesterol
metabolism in the liver
The expression levels of genes related to cholesterol bio-
synthesis and catabolism in the liver were analyzed by
real-time quantitative PCR (Figure 1A). The mRNA ex-
pression level of HMG-CoA reductase (HMGCR), a
rate-limiting enzyme in cholesterol synthesis, tended to
Table 3 Tissue weights and cholesterol contents in the
liver, epididymal WAT, and muscle
Control Fucoxanthin
Liver Weight (g) 1.62 ± 0.05 1.87 ± 0.05**
Cholesterol (mg/liver) 11.10 ± 0.89 6.58 ± 0.19**
Epididymal WAT Weight (g) 1.44 ± 0.12 0.99 ± 0.10*
Cholesterol
(mg/epididymal WAT)
14.76 ± 1.33 10.26 ± 0.96**
Muscle Weight (g) 0.23 ± 0.01 0.23 ± 0.01
Cholesterol (mg/muscle) 0.23 ± 0.02 0.23 ± 0.01
KK-Ay mice were fed with the AIN-93G diet with or without 0.2% fucoxanthin
for 4 weeks. Cholesterol contents in tissues were measured by an enzymatic
methods as shown in “Materials and Methods”. Each value represents the
mean ± standard error (n = 6). Asterisks show significant differences from the
control group (*P < 0.05<, **P < 0.01).
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that of lanosterol synthase (LSS), the mRNA expression
level of key enzymes involved in cholesterol biosynthesis,




















































Figure 1 Hepatic gene expression involved in cholesterol
metabolism. KK-Ay mice were fed with the AIN-93G diet with or
without 0.2% fucoxanthin for 4 weeks. Total RNA was extracted from
the liver and processed for quantitative real-time PCR analysis as
described under “Materials and Methods”. The expression levels of
each mRNA are normalized to β-actin levels. Data are presented
relative to the control group. Each value represents the
mean± standard error (n = 6). HMGCR: HMG-CoA reductase, HMGCS:
HMG-CoA synthase, FDPS: farnesyl diphosphate synthase, LSS:
lanosterol synthase, CYP51: lanosterol 14α-demethylase, CYP7A1:
cholesterol 7 α-hydroxyrase.diphosphate synthase (FDPS), and lanosterol 14α-
demethylase (CYP51), tended to be increased by fuco-
xanthin. In contrast, the mRNA expression level of
CYP7A1, an enzyme associated with synthesis of bile
acids from cholesterol, did not increase by fucoxanthin-
diet (Figure 1B). Overall, the mRNA expression of
enzymes involved in cholesterol synthesis tended to
be higher in the fucoxanthin-fed mice, although not
significantly.
We further examined the expression levels of SREBP1
and SREBP2, which are key transcriptional factors for
the regulation of cholesterol metabolism. As shown in
Figure 2, dietary fucoxanthin resulted in a 2.7-fold in-
crease in SREBP2 expression compared with control
mice. SREBP1 expression was also significantly increased
in the fucoxanthin-fed mice. In particular, SREBP2 is
known to be sensitively activated and to enhance gene
transcription for cholesterol synthesis when cellular
cholesterol levels decline [11,12]. Our results show that
SREBP2 and SREBP1 expression was enhanced in the
liver by fucoxanthin-diet, although hepatic cholesterol
content in the mice fed fucoxanthin was lower than that
in the control mice.LDLR, SR-B1, and ABCA1 expressions involved in
cholesterol uptake and transport in the liver
To understand how serum cholesterol levels increased
and hepatic cholesterol content decreased by fucoxan-
thin, we next examined cholesterol uptake-related pro-
teins, LDLR and SR-B1, which are receptors for LDL
and cholesteryl esters from HDL in the liver. LDLR ex-
pression levels in the liver were markedly decreased by
fucoxanthin (Figure 3). SR-B1 expression levels were also
significantly lower in the KK-Ay mice fed fucoxanthin
than in the control mice (Figure 3). The reduced LDLR
and SR-B1 expression levels in the liver indicated that
fucoxanthin suppresses the uptake of LDL particles and
HDL-cholesterol from the blood into the liver. On the
other hand, the expression levels of ABCA1, which is a
key factor for cholesterol efflux from the liver [13], were
not significantly different between the control and fuco-
xanthin group.Hepatic expression of PCSK9 mRNA involved in LDLR
degradation
PCSK9, a member of the subtilisin family of serine
proteases, has been shown to induce intracellular deg-
radation of LDLR [14,15]. Fucoxanthin induced a 2-
fold increase in hepatic expression of PCSK9 mRNA
(Figure 4). This result suggests that reduced hepatic
LDLR expression was due to PCSK9-associated LDLR






















































Figure 2 SREBP1 and SREBP2 expressions in the liver. KK-Ay mice were fed with the AIN-93G diet with or without 0.2% fucoxanthin for
4 weeks. Liver lysates were prepared for Western blotting, and primary antibody binding was detected by appropriate secondary antibodies for
chemiluminescence as described under “Materials and Methods”. SREBP1 and SREBP2 levels are presented relative to control group after
normalization for β-Actin levels. Each value represents the mean± standard error (n = 6). Asterisks show significant differences from the control
group (** P < 0.01).
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Fucoxanthin from edible brown seaweeds have reported
to show anti-obesity effect on diabetic/obese KK-Ay mice
and high-fat-fed C57BL/6N mice [7,16]. A fucoxanthin
and conjugated linolenic acid-containing supplement has
also been reported to induce weight loss and reduce the
body and liver fat levels in obese non-diabetic women
[17]. On the other hand, we and another group observed
that fucoxanthin increases serum total cholesterol levels
in rodents [5,6]. Cholesterol is an important component
of cell membranes and is required for the biosynthesis of
bile acids and vitamin D. However, an excessive serum
cholesterol level, particularly LDL cholesterol, is known
to be a risk factor for atherosclerosis. Therefore, we
investigated the mechanisms underlying the increase in
serum cholesterol levels induced by fucoxanthin.
In this study, we observed increased HDL-cholesterol
and non-HDL-cholesterol levels as well as total choles-
terol levels in the serum of diabetic/obese KK-Ay mice
fed fucoxanthin. Dietary fucoxanthin also significantly
increased the expression of SREBP2 and SREBP1, which
are key transcriptional factors involved in up-regulation
of cholesterol synthesis. Further, the mRNA expression
levels of HMGCR, HMGCS, FDPS, and CYP51, which
are involved in cholesterol synthesis, tended to increase
in the fucoxanthin-fed mice compared with the control
mice, although these differences were not statistically
significant. These results show that fucoxanthin slightly
enhances cholesterol synthetic pathway in the liver. In
contrast, hepatic cholesterol content decreased in the
fucoxanthin-diet group.To determine how fucoxanthin regulated cholesterol
metabolism we considered the balance between choles-
terol biosynthesis, efflux, and its incorporation in tissues.
SR-B1 is known to play an important role in selectively
incorporating cholesteryl esters from circulating HDL
into cells. Mice with attenuated hepatic SR-B1 expres-
sion had reduced selective HDL-cholesterol clearance
and increased HDL-cholesterol levels in their blood
[18,19]. Conversely, plasma HDL-cholesterol levels were
dramatically decreased in mice that overexpressed hep-
atic SR-B1 [20]. Non-HDL-cholesterol levels, mostly
LDL-cholesterol levels are determined, in part, by the
rate at which LDL particles are taken up and removed
from the circulation by LDLR [21]. The SR-B1 and
LDLR proteins expressed in the liver at high levels and
their hepatic expressions have a significant impact on
circulating cholesterol levels [22]. In the present study,
fucoxanthin resulted in reduced SR-B1 and LDLR ex-
pression in the liver of the KK-Ay mice, whereas no dif-
ferences were observed in the cholesterol efflux factor
ABCA1 [23]. These results show that the increased
serum cholesterol levels resulted from the reduced hep-
atic clearance of serum cholesterol via down-regulation
of SR-B1 and LDLR by fucoxanthin. In particular, the
decrease in hepatic cholesterol content suggests that the
reduction of incorporation of serum cholesterol may
predominate over the endogenous cholesterol biosyn-
thesis in KK-Ay mice.
Adipose tissue is also known to store large amounts of
cholesterol and contributes to regulation of circulating










































































Figure 3 Effect of fucoxanthin on expression levels of cholesterol transport-related proteins in the liver. KK-Ay mice were fed with the
AIN-93G diet with or without 0.2% fucoxanthin for 4 weeks. Liver lysates were prepared for Western blotting, and primary antibody binding was
detected by appropriate secondary antibodies for chemiluminescence as described under “Materials and Methods”. Expression levels are
presented relative to control group after normalization for β-Actin levels. Each value represents the mean± standard error (n = 6). Asterisks show
significant differences from the control group (* P < 0.05, ** P < 0.01).
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ment of obesity, which resulted in attenuation of choles-
terol estimations in WAT. On the other hand, dietary
fucoxanthin also increased the serum cholesterol levels
in non-obese ICR mice without suppressing their body
weight gain [6]. Taken together, these results suggest that
the increase in serum cholesterol levels observed in the
KK-Ay mice were partly due to the suppression of fat
accumulation by dietary fucoxanthin.
Thus, we have shown for the first time that dietary fuco-
xanthin leads to increased HDL and non-HDL-cholesterol
levels in KK-Ay mice through down-regulation of hepatic
LDLR and SR-B1 expression, while fucoxanthin increases
the expression of SREBP2, which up-regulates LDLR. As
one possible mechanism, we propose that LDLR post-
transcriptional regulation is involved.Recent studies have demonstrated LDLR post-
transcriptional regulation by proprotein convertase sub-
tilisin/kexin type 9 (PCSK9) [26,27] and LXR/inducible
degrader of LDLR (IDOL) signaling pathways [28].
PCSK9 is primarily expressed in the liver, small intestine,
and kidneys [29]. PCSK9 binds to the EGF-A extracellu-
lar domain of LDLR and subsequently triggers its intra-
cellular degradation in lysosomes [30]. In addition,
PCSK9 overexpression in mice reduced LDLR levels and
increased non-HDL-cholesterol levels [31]. Interestingly,
PCSK9 has been identified as a SREBP target gene
[32,33]. It is noteworthy that PCSK9 mRNA expression
was up-regulated by fucoxanthin. These results suggest
that fucoxanthin promotes LDLR degradation through
PCSK9 mRNA up-regulation in the SREBP2 signaling


























Figure 4 Effect of fucoxanthin on expression levels of PCSK9
mRNA in the liver. KK-Ay mice were fed with the AIN-93G diet with
or without 0.2% fucoxanthin for 4 weeks. Total RNA was extracted
from the liver and processed for quantitative real time PCR analysis
as described under “Materials and Methods”. PCSK9 mRNA
expression levels are normalized to β-actin levels. Data are presented
relative to control group. Each value represents the mean± standard
error (n = 6). Asterisks show significant differences from the control
group (** P < 0.01).
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by fucoxanthin.
On the other hand, it has been reported that hepatic
SR-B1 expression is regulated by a variety of dietary
components, hormonal, metabolic, and pharmacological
manipulations [22,34]. Nuclear receptors components
such as liver X receptor (LXR) and peroxisome
proliferator-activated receptor-α (PPARα) are also
known to regulate hepatic SR-B1 expression [35,36]. In
this study, we could not identify a key factor to suppress
SR-B1 by fucoxanthin. Further investigation is required
to clarify the effect of fucoxanthin on SR-B1 expression.
In this study, we showed for the first time that dietary
fucoxanthin resulted in increased serum HDL and non-
HDL-cholesterol levels as well as total cholesterol levels
via the activation of SREBP signaling and by suppressing
serum cholesterol uptake in the liver via decreasing
LDLR and SR-B1 expression. Further, our results suggest
that LDLR degradation is promoted by fucoxanthin
through up-regulation of PCSK9 and leads to increased
non-HDL-cholesterol levels. These findings provide im-
portant insights on the effects of fucoxanthin on choles-
terol and lipoprotein metabolism. However, it is unclear
whether the responses to cholesterol metabolism are
specific for rodents or common to human. Dysfunction
of cholesterol metabolism is strongly associated with ar-
teriosclerosis. Therefore, it will be necessary to furtherinvestigate the influence of high serum cholesterol levels
induced by fucoxanthin on human health.
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